Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer

Journal of the National Cancer Institute

Volumn 95, Issue 20, 2003, Pages 1545-1548

  Hershman, Dawn ^a,d   Weinberg, Mitchell ^b   Rosner, Zachary ^b   Alexis, Karenza ^b   Tiersten, Amy ^c   Grann, Victor R ^a,b   Troxel, Andrea ^b   Neugut, Alfred I ^a,b  

^a Columbia University ^*  (United States)

^b New York University ^*  (United States)

^c NEW YORK UNIVERSITY   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NEGRO; NEUTROPENIA; PRIORITY JOURNAL; RACE DIFFERENCE; STATISTICAL SIGNIFICANCE; ADULT; AFRICAN AMERICAN; AGED; BREAST TUMOR; CASE CONTROL STUDY; CAUCASIAN; CHEMICALLY INDUCED DISORDER; ETHNOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 0142022663     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg073     Document Type: Article

References (20)

1. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002; 162: 1985-93.
2. Joslyn SA, West MM. Racial differences in breast carcinoma survival. Cancer 2000;88: 114-23.
3. Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 1994;86:705-12.
4. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 1996;49:664-6.
5. Shoenfeld Y, Weinberger A, Avishar R, Zamir R, Gazit E, Joshua H, et al. Familial leukopenia among Yemenite Jews. Isr J Med Sci 1978;14:1271-4.
6. Mason BA, Lessin L, Schechter GP. Marrow granulocyte reserves in black Americans. Hydrocortisone-induced granulocytosis in the "benign" neutropenia of the black. Am J Med 1979;67:201-5.
7. Phillips D, Rezvani K, Bain BJ. Exercise induced mobilisation of the marginated granulocyte pool in the investigation of ethnic neutropenia. J Clin Pathol 2000;53:481-3.
8. Bain BJ, Phillips D, Thomson K, Richardson D, Gabriel I. Investigation of the effect of marathon running on leucocyte counts of subjects of different ethnic origins: relevance to the aetiology of ethnic neutropenia. Br J Haematol 2000;108:483-7.
9. Beahrs OH, Henson DE, Hurter RV, Kennedy BJ. Manual for staging of cancer. 4th ed. Philadelphia (PA): J.B. Lippincott; 1992. p. 164.
10. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
11. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32.
12. Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998;16:2392-400.
13. Lerma P, Besa E, Klease C, Joseph R, Ozer H. Benign neutropenia patients are subjected to frequent treatment delays when current treatment guidelines are used [abstract 1627]. Proc ASCO 1999;18:422a.
14. Lyman GH. A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy 2000;20:104S-11S.
15. Hryniuk W. Importance of chemotherapy scheduling: pieces of the puzzle. Cancer Invest 1999;17:545-6.
16. Hryniuk W. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1999;91:1425.
17. Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, et al. Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 1989;12:481-5.
18. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
19. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11.
20. Ottevanger PB, De Mulder PH, Grol RP, Van Lier H, Beex LV. Effects of quality of treatment on prognosis in primary breast cancer patients treated in daily practice. Anticancer Res 2002;22:459-65.